PMX464, a thiol‐reactive quinol and putative thioredoxin inhibitor, inhibits NF‐κB‐dependent proinflammatory activation of alveolar epithelial cells
Open Access
- 1 November 2008
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 155 (5), 661-672
- https://doi.org/10.1038/bjp.2008.258
Abstract
Subtle changes in the intracellular reduction-oxidation (redox) state can modulate nuclear factor-kappaB (NF-kappaB) activity. Thioredoxin-1 (Trx) is a small, ubiquitous, redox-active thiol (-SH) protein that, with thioredoxin reductase-1 (TrxR), modifies the redox status of NF-kappaB pathway components. PMX464 is a novel thiol-reactive quinol thought to inhibit the Trx/TrxR system. The aim of this work was to investigate whether PMX464 inhibited NF-kappaB-mediated proinflammatory activation of human type II alveolar epithelial cells (A549). Intercellular adhesion molecule-1 (ICAM-1), granulocyte-macrophage colony-stimulating factor (GM-CSF) and CXCL8, NF-kappaB DNA binding, nuclear translocation of NF-kappaB p65 subunit, IkappaBalpha degradation, IkappaB phosphorylation and IkappaB kinase (IKK) activity were assessed in A549 cells stimulated with IL-1beta with or without PMX464 pretreatment. Effects of PMX464 on ICAM-1 expression in human lung microvascular endothelial cells (HLMVEC) were also investigated. For comparison, selected measurements (ICAM-1 and IkappaB-alpha phospho-IkappaB-alpha) were made on A549 cells after RNA interference-mediated silencing (siRNA) of Trx. PMX464 reduced ICAM-1, GM-CSF and CXCL8 expression in IL-1beta-stimulated A549 cells and ICAM-1 in HLMVEC. PMX464 inhibited IL-1beta-induced NF-kappaB DNA binding, nuclear translocation of NF-kappaB p65 subunit and factors involved in NF-kappaB activation; specifically, IkappaBalpha degradation, IkappaB phosphorylation and IkappaB kinase (IKK) activity in A549. By contrast, Trx siRNA did not alter ICAM-1 expression or IkappaBalpha degradation/phosphorylation in IL-1beta-stimulated A549 cells. PMX464 inhibits a proinflammatory response in A549 cells targeting the NFkappaB pathway above IKK. The lack of effect with Trx siRNA suggests that PMX464 acts on thiol proteins, in addition to Trx, to elicit anti-inflammatory responses in lung epithelial cells.Keywords
This publication has 39 references indexed in Scilit:
- Guide to Receptors and Channels (GRAC), 3rd editionBritish Journal of Pharmacology, 2008
- A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell linesBritish Journal of Pharmacology, 2007
- Antitumor quinols: Role of glutathione in modulating quinol-induced apoptosis and identification of putative cellular protein targetsBiochemical and Biophysical Research Communications, 2006
- Extracellular thioredoxin levels are increased in patients with acute lung injuryThorax, 2006
- Role of thioredoxin‐1 in apoptosis induction by α‐tocopheryl succinate and TNF‐related apoptosis‐inducing ligand in mesothelioma cellsFEBS Letters, 2006
- Current Concepts of Redox Signaling in the LungsAntioxidants and Redox Signaling, 2006
- Inhibitors of Protein Kinase C (PKC) Prevent Activated TranscriptionPublished by Elsevier ,2004
- AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-α in Jurkat leukemic cellsOncogene, 2003
- Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunitExperimental & Molecular Medicine, 2003
- Identification of a Novel Inhibitor of the NF-κB PathwayCurrent Medicinal Chemistry -Anti- Inflammatory & Anti-Allergy Agents, 2002